439 related articles for article (PubMed ID: 35672793)
1. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D; Constantinescu C; Vrancken L; Rasche L; Gregoire C; Tigu B; Gulei D; Dima D; Tanase A; Einsele H; Ciurea S; Tomuleasa C; Caers J
J Hematol Oncol; 2022 Jun; 15(1):78. PubMed ID: 35672793
[TBL] [Abstract][Full Text] [Related]
2. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
3. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
4. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D
Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327
[TBL] [Abstract][Full Text] [Related]
5. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
6. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism of action and clinical results of immunotherapy for multiple myeloma].
Imai Y
Rinsho Ketsueki; 2022; 63(9):1180-1187. PubMed ID: 36198543
[TBL] [Abstract][Full Text] [Related]
8. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
Martino M; Paviglianiti A
Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
[No Abstract] [Full Text] [Related]
9. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
Xia J; Li Z; Xu K
J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
[TBL] [Abstract][Full Text] [Related]
10. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
Guo R; Lu W; Zhang Y; Cao X; Jin X; Zhao M
Front Immunol; 2022; 13():839097. PubMed ID: 35320942
[TBL] [Abstract][Full Text] [Related]
11. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.
Braunstein M; Weltz J; Davies F
Expert Rev Hematol; 2021 Apr; 14(4):377-389. PubMed ID: 33769179
[TBL] [Abstract][Full Text] [Related]
12. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
Sunder-Plassmann V; Aksoy O; Lind J; Pecherstorfer M; Vallet S; Podar K
Expert Opin Pharmacother; 2022 Aug; 23(12):1425-1444. PubMed ID: 35829636
[TBL] [Abstract][Full Text] [Related]
13. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
14. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
Hammons L; Haider S; Portuguese AJ; Banerjee R; Szabo A; Pasquini M; Chhabra S; Radhakrishnan S; Mohan M; Narra R; Dong J; Janz S; Shah NN; Hamadani M; D'Souza A; Hari P; Dhakal B
Br J Haematol; 2024 Mar; 204(3):887-891. PubMed ID: 38054558
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies as an addition to current myeloma therapy strategies.
Jullien M; Touzeau C; Moreau P
Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
[TBL] [Abstract][Full Text] [Related]
17. Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma.
Awuah D; Minnix M; Caserta E; Tandoh T; Adhikarla V; Poku E; Rockne R; Pichiorri F; Shively JE; Wang X
Cancer Immunol Immunother; 2023 Aug; 72(8):2841-2849. PubMed ID: 37209218
[TBL] [Abstract][Full Text] [Related]
18. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
Cho SF; Xing L; Anderson KC; Tai YT
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885245
[TBL] [Abstract][Full Text] [Related]
19. T cell-engaging therapies - BiTEs and beyond.
Goebeler ME; Bargou RC
Nat Rev Clin Oncol; 2020 Jul; 17(7):418-434. PubMed ID: 32242094
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.
Susanibar Adaniya SP; Cohen AD; Garfall AL
Am J Hematol; 2019 May; 94(S1):S28-S33. PubMed ID: 30730071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
